Every material Form 8-K Colgate-Palmolive filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Colgate-Palmolive reported third quarter 2025 net sales of $5.1 billion, up 2.0%, and GAAP diluted EPS of $0.91, up 1%, though organic sales rose only 0.4%. The company lowered its full-year organic sales growth outlook to 1% to 2% from the low end of 2% to 4%, kept its EPS outlook, and disclosed a three-year productivity program with $200 million to $300 million of pre-tax charges, substantially all incurred by December 31, 2028.
Q3 2025 net sales $5,131 million, up 2.0%; organic sales up 0.4%
GAAP diluted EPS $0.91 versus $0.90 a year earlier; GAAP gross profit margin 59.4%, down 170 basis points
Full-year 2025 organic sales growth now expected at 1% to 2%, versus the low end of 2% to 4% previously; EPS still expected up low single digits
Strategic Growth and Productivity Program: cumulative pre-tax charges of $200 million to $300 million, with about 75% to 85% expected to be cash expenditures
Colgate-Palmolive reported second-quarter 2025 net sales of $5,110 million, up 1.0%, and GAAP diluted EPS of $0.91, up 2%, while narrowing its full-year organic sales growth outlook to the low end of 2% to 4%. The company also approved a three-year productivity program with projected pre-tax charges of $200 million to $300 million, which will weigh on reported results through December 31, 2028.
Q2 2025 net sales were $5,110 million, up 1.0%; organic sales rose 1.8%, including a 0.6% negative impact from lower private label pet sales.
GAAP diluted EPS was $0.91, up from $0.89; GAAP gross profit margin fell 50 basis points to 60.1%.
Full-year 2025 organic sales growth is now expected at the low end of 2% to 4%; GAAP EPS is still expected to rise low single digits.
The productivity program carries projected cumulative pre-tax charges of $200 million to $300 million over three years, with substantially all incurred by December 31, 2028, recorded in the Corporate segment.
Colgate-Palmolive's board elected Shane Grant, formerly of Group Danone, as Chief Operating Officer, Americas, effective June 16, 2025, with a base salary of $1,100,000 and a target bonus of 115% of salary. The filing also says Prabha Parameswaran will become Vice Chair and retire on October 1, 2025, and names new operating and growth roles for two other executives.
Shane Grant, 50, joins from Group Danone, where he was Group Deputy CEO and CEO Americas; he will report to CEO Noel R. Wallace
Grant's package includes a 90,000-unit restricted stock unit replacement award and a $1,000,000 sign-on bonus plus a $1,500,000 transition allowance
Prabha Parameswaran, Group President, Growth and Strategy, plans to retire October 1, 2025 and becomes Vice Chair effective June 16, 2025
Panagiotis Tsourapas and John Hazlin receive promotions to Chief Operating Officer roles and Chief Growth Officer, respectively, effective June 16, 2025
Colgate-Palmolive reported first-quarter 2025 results with net sales down 3.1% to $4,911 million, mainly because foreign exchange was a 4.4% headwind, while organic sales rose 1.4%. GAAP diluted EPS rose 2% to $0.85, and the company updated its full-year 2025 guidance, now expecting organic sales growth of 2% to 4% and EPS up low single digits on a GAAP basis.
Net sales were $4,911 million, down 3.1% from $5,065 million; foreign exchange was a 4.4% headwind.
GAAP diluted EPS was $0.85 versus $0.83; Base Business (non-GAAP) EPS was $0.91 versus $0.86.
For full-year 2025, the company now expects organic sales growth of 2% to 4% and GAAP EPS up low single digits.
Hill's operating profit rose 30% to $258 million, while Latin America net sales fell 8.7%.
Colgate-Palmolive reported fourth quarter and full year 2024 results. Fourth quarter net sales were $4,944 million, down 0.1%, while GAAP diluted EPS rose 3% to $0.90. For the full year, net sales reached $20.1 billion (up 3.3%) and GAAP diluted EPS rose 27% to $3.51. For 2025, the company expects roughly flat net sales and mid-single-digit GAAP EPS growth.
Q4 2024 net sales $4,944 million, down 0.1%; organic sales up 4.3%
Q4 2024 GAAP diluted EPS $0.90, up 3%; Base Business EPS $0.91, up 5%
Full year 2024 net sales $20.1 billion, up 3.3%; GAAP diluted EPS $3.51, up 27%
2025 guidance: net sales roughly flat, including a mid-single-digit negative FX impact; GAAP EPS growth mid-single-digit
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Colgate-Palmolive filing is on SEC EDGAR ↗. 8-K briefs of other companies →